When a nursing-home resident takes medication for a mental health condition or distressing symptoms, a review should help everyone understand its purpose, benefits, and risks. Residents and families can contribute observations that make the discussion more useful: what has improved, what has changed, and what matters most to the person receiving care.
Psychotropic medications affect mental processes or behavior. The category includes antidepressants, antipsychotics, medicines for anxiety, and sleep medicines. These treatments have different uses and risks. A medication's name or category alone does not explain why it was prescribed for a particular person. NIMH provides an overview of mental health medications.
Begin with the treatment goal
Ask the prescriber to describe the condition being treated and the specific improvement the team hopes to see. What symptoms were present before treatment? How often did they occur? How will the team judge whether treatment is helping?
The discussion should include the resident's priorities and the effects of treatment on everyday life. Ask about expected benefits, possible adverse effects, and any monitoring needed for that medicine. For some antipsychotics, monitoring can include weight, blood glucose, and lipid levels. Other medicines have different requirements. NIMH's medication guidance emphasizes matching treatment to the individual's needs and medical circumstances.
Avoid reducing a complex discussion to whether a medicine is “good” or “bad.” A useful question is: “What evidence tells us this treatment is still helping this person, and what problems should we watch for?”
Understand the nursing-home review process
In Medicare- and Medicaid-certified nursing homes, federal requirements include a licensed pharmacist's review of each resident's medication regimen at least monthly. Psychotropic treatment requires a documented clinical reason and monitoring. Residents receiving these drugs must receive gradual dose reductions and behavioral interventions unless clinically contraindicated. The care team must assess the individual resident. CMS State Operations Manual, Appendix PP, F605 and F756.
CMS revised its surveyor guidance effective April 28, 2025, consolidating unnecessary psychotropic medication guidance under F605, which also addresses chemical restraints. The guidance protects residents from medications used for discipline or staff convenience rather than treatment of medical symptoms. CMS's revised guidance memorandum.
What gradual dose reduction means
A gradual dose reduction, often called GDR, is a supervised, stepwise reduction to evaluate whether symptoms can be managed with less medication or whether it can be discontinued. Timing depends on the medicine, the resident's condition, other treatments, and previous responses.
A reduction may be clinically contraindicated when it is likely to worsen an underlying disorder or impair function. A previous attempt that caused symptoms to return may be relevant. The physician must document the clinical rationale; the diagnosis alone does not explain the decision. Ask what will be monitored and when the plan will be reassessed. CMS Appendix PP, F605, gradual dose reduction guidance.
Do not abruptly stop or independently change a psychotropic medication. FDA warns that abrupt discontinuation or rapid reduction of benzodiazepines can cause dangerous withdrawal, including seizures, and that tapering plans must be individualized. FDA benzodiazepine safety communication.
Look at the circumstances around symptoms
For someone with dementia, a change in behavior can have several contributors. Pain, constipation, hunger, sleep problems, difficulty hearing or seeing, medication effects, and an overwhelming environment can all matter. A sudden or rapidly fluctuating change warrants prompt attention from the clinical team.
Families can describe routines, familiar activities, communication preferences, and situations that seem to increase distress. A short record of when a change happens and what came before it can help the team look for patterns. Ask which approaches have been tried, what helped, and how helpful measures will continue. NIA guidance on behavior changes in Alzheimer's disease.
Leave with a shared plan
Before a care conference ends, ask who will follow up, what changes to report, and how to contact the team. Discuss medicine-specific warnings: antipsychotics carry an increased-mortality warning for older adults with dementia-related psychosis. Approved uses and risks depend on the drug and condition. FDA explains this warning in its brexpiprazole approval announcement.
This article is general education, not an individualized treatment or tapering plan. Decisions should be made with the resident, their authorized representative when applicable, and the treating team.